Boehringer Ingelheim | sciencenewsnet.in

Breaking News

Technological Breakthrough in Carbon Nanotube Applications for Battery Dry Process

Lack of control at work identified as cause for physician burnout and attrition

Expanding HPV vaccination to all adults aged 27-45 years unlikely to be cost-effective or efficient for HPV-related cancer prevention

University Student’s Start-Up Expands, Connecting Small Coffee Farmers to the World

FSU physicists will study nuclear reactions of stars with support from National Science Foundation

Warning: don’t miss Thanksgiving dinner, it’s more meaningful than you think

Roswell Park Launches First-of-Its-Kind Oncology Training Program for Nurse-Scientists With $2M NCI Grant

UT Southwestern brings first-of-its-kind radiation oncology to new $177M campus in Fort Worth Medical District

Tips and recipes for a healthy holiday season from a doctor and a dietitian

X-ray Measurements Reveal an Unexpected Role for Copper in Photocatalysts

26 Nov, 2024

MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer

April 14, 2021 sarah JonasAnnouncement

MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer.